Dexamethasone
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Dexamethasone: Alopecia mucinosa
One-Sentence Summary
Dexamethasone is a corticosteroid with broad anti-inflammatory and immunosuppressive activity. The TxGNN model predicts it may be useful for alopecia mucinosa, but the prediction is supported only by the model score. The data compiled for this report contain no clinical trials and no publications on this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for dexamethasone is not available in the compiled data. Dexamethasone is a systemic corticosteroid. Corticosteroids are generally used in inflammatory follicular and dermal conditions, so an anti-inflammatory effect on alopecia mucinosa is plausible in principle.
This rationale is general. No dexamethasone-specific mechanism, study or case data for alopecia mucinosa were provided. The only support is the high model score (0.9999), so the prediction is a hypothesis for further investigation, not an evidence-based recommendation.
The only Australian licence on record is an intravitreal (eye) injection. Route compatibility with a skin or hair-follicle condition has not been assessed and would need to be addressed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10943Y | Ozurdex | Intravitreal injection 700 micrograms | Not stated in the data compiled for this report |
This is a single-ingredient product, and its licence is currently valid.
Safety Considerations
- Drug Interactions: The compiled data list 100 recorded interactions. Examples by severity:
- Major: fentanyl, adalimumab.
- Moderate: paclitaxel, zidovudine, abemaciclib, acalabrutinib, acarbose, acetazolamide, acebutolol, codeine, dihydrocodeine, ibuprofen, ketorolac, isotretinoin, nifedipine, tetanus toxoid vaccine.
- Minor: dolutegravir, lidocaine, formoterol.
- Conditions flagged for caution (disease-level data, not label text): hypertension, congestive heart failure, hyperglycaemia, epilepsy, measles, herpes simplex keratitis, pituitary hormone deficiencies (including hypopituitarism and growth hormone deficiency), hypogonadotropic hypogonadism (including Kallmann syndrome), and certain urea cycle disorders (carbamoyl phosphate synthetase I deficiency, citrullinemia, hyperargininemia).
TGA-approved Product Information (PI) warnings and contraindications were not available in the compiled data. Please refer to the PI for authoritative safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no trials, no publications and no dexamethasone-specific mechanistic data for alopecia mucinosa (evidence level L5). The only Australian licence is an intravitreal product, which does not match a dermatological use.
To proceed, the following is needed:
- Literature review for case reports or studies of corticosteroids in alopecia mucinosa
- Mechanism of action data for dexamethasone
- Assessment of suitable routes and formulations for a skin or hair-follicle condition
- TGA Product Information warnings and contraindications for a safety screen
- A comparison with current standard treatment for the condition
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.